Hints and tips:
...Mikael Dolsten, Pfizer’s chief scientific officer, said the group would aim to ease the side effects and improve its study design and execution in its future studies of the daily pill....
...Dolsten, Pfizer’s chief scientific officer....
...Mikael Dolsten, Pfizer’s chief scientific officer, said the pair were continuing “our journey of discovery together, by advancing mRNA technology to tackle another health challenge ripe for scientific innovation...
...Mikael Dolsten did not talk about the vaccine that would later bring the company fame and enormous wealth: instead, in those early days, he described how the drugmaker was working on a way to treat patients...
...Mikael Dolsten, Pfizer’s chief scientific officer, told investors that the US drugmaker is “very intrigued by the use of mRNA for flu” because it can generate a good response from T cells, white blood cells...
...Dolsten, chief scientific officer at Pfizer....
...Mikael Dolsten, chief scientific officer at Pfizer, said the antiviral treatment had “demonstrated potent” activity against Sars-Cov-2, the virus that causes Covid-19, as well as other coronaviruses....
...Mikael Dolsten, Pfizer’s chief scientific officer, said that the focus of the company’s business development was switching from revenue in the short term to shoring up the pipeline in the mid term....
...• Mikael Dolsten, global president for worldwide research and development, will also assume oversight of the Chief Medical Officer’s role....
...Pfizer’s most senior scientist Mikael Dolsten says checkpoint inhibitors have had remarkable results and will come to fight up to 80 per cent of cancers. The most promising are yet to come, he says....
...Mikael Dolsten, Pfizer’s research and development chief, said that grouping several drugs into a single treatment plan could extend the benefits of existing immunotherapies....
...Dr Mikael Dolsten, president of worldwide research and development at Pfizer, said he was aware of the unease but that the combined company would occupy a “sweet spot” in R&D....
...Development, AstraZeneca Steve Bates Chief Executive, BioIndustry Association Harpal Kumar Chief Executive, Cancer Research UK Patrick Vallance President of Pharmaceuticals R&D, GlaxoSmithKline Mikael...
...Monday saw Pfizer’s research chief, Mikael Dolsten, penning a comment piece in the free-sheet, which began thusly: This week, I will be giving evidence before the UK Parliament’s Science and Technology...
...Mr Mackay will have greater power than at US-based Pfizer, where he had shared responsibility for research and development on the executive team with Mikael Dolsten, a senior scientist, and other managers...
International Edition